Skip to main content
. 2018 Mar 28;8(9):2459–2476. doi: 10.7150/thno.23880

Figure 6.

Figure 6

Albumin binding, pharmacokinetics, and antitumor effect of ABD-TRAIL. (A) Albumin binding of ABD-TRAIL analyzed by SEC and ELISA. (B) Affinity of ABD-TRAIL for HSA measured by biolayer interferometry. ABD-TRAIL was captured by anti-His tag antibody-coated biosensor prior to association in solution containing increasing concentration of HSA. (C) FcRn binding of HSA preincubated with ABD-TRAIL and time-dependent clearance of ABD-TRAIL. (D)Time-dependent decrease of cytotoxicity of ABD-TRAIL. (E) Affinity of ABD-TRAIL for DR4-Fc and DR5-Fc. (F) In vivo antitumor effect. ABD-TRAIL (5 mg/kg) was intravenously into mice bearing COLO 205 tumor grafts at the indicated times. The tumor volume was measured every day. At the end of the experiment, tumor grafts were removed and weighed.